Skip to main content

Advertisement

Table 1 Baseline patient characteristics (n = 90)

From: Retrospective study of RAS/PIK3CA/BRAF tumor mutations as predictors of response to first-line chemotherapy with bevacizumab in metastatic colorectal cancer patients

Characteristic N (%)
Sex
 Male 48 (53.3)
 Female 42 (46.7)
Median age (range), years 63 (27–79)
ECOG performance status
 0 82 (91.1)
 1, 2 8 (8.9)
Site of primary tumor
 RCC (cecum to the transverse colon) 34 (37.8)
 LCRC (descending to the rectosigmoid colon) 40 (44.4)
 Rectum 16 (17.8)
Mode of metastasis
 Synchronous 77 (85.6)
 Asynchronous 13 (14.4)
Sites of metastasis
 Liver 51
 Lung 38
 Distant lymph nodes 29
 Peritoneum 23
Histology
 Differentiated 83 (92.2)
 Undifferentiated 7 (7.8)
Number of metastases
 1 37 (41.1)
  ≥ 2 53 (58.9)
Chemotherapy regimen
 FOLFOX4/mFOLFOX6 or XELOX 86 (95.6)
 FOLFIRI 4 (4.4)
Prior metastatectomy
 Yes 12 (13.3)
 No 78 (86.7)
Resection of primary tumor
 Yes 67 (74.4)
 No 23 (25.6)
Previous oxaliplatin treatment as adjuvant CTx
 Yes 13 (14.4)
 No 77 (85.6)
KRAS status (codon 12,13)
 Wild-type 47 (52.2)
 Mutant 43 (47.8)
RAS status (KRAS/NRAS)
 Wild-type 42 (46.7)
 Mutant 48 (53.3)
PIK3CA status
 Wild-type 82 (91.1)
 Mutant 8 (8.9)
BRAF status
 Wild-type 82 (91.1)
 Mutant 8 (8.9)
  1. ECOG Eastern Cooperative Oncology Group, RCC right-sided colon cancer, LCRC left-sided colorectal cancer, CTx chemotherapy